Table 2.
Rate and HR for ART eligibility by baseline covariates
| N | Events/pyr | Rate/100 pyr | Crude HR (95% CI) | Adjusted HR (95% CI) | |
|---|---|---|---|---|---|
|
| |||||
| Overall | 301 | 156/428.4 | 36.4 | ||
| Study arm | |||||
| Placebo | 153 | 85/205.7 | 41.3 | 1.0 | 1.0 |
| Treatment | 148 | 71/222.7 | 31.9 | 0.78 (0.57 to 1.07) | 0.67 (0.48 to 0.92) |
| Age (years) | |||||
| 20–29 | 73 | 42/103.1 | 40.7 | 1.0 | 1.0 |
| 30–39 | 131 | 68/185.0 | 36.8 | 0.92 (0.63 to 1.36) | 1.02 (0.69 to 1.51) |
| 40–49 | 66 | 34/97.1 | 35.0 | 0.89 (0.57 to 1.40) | 1.15 (0.73 to 1.83) |
| 50+ | 31 | 12/43.2 | 27.8 | 0.72 (0.38 to 1.37) | 0.91 (0.47 to 1.74) |
| CD4+ T cell count | |||||
| 300–349 | 135 | 89/174.9 | 50.9 | 1.0 | 1.0 |
| 350–499 | 166 | 67/253.5 | 26.4 | 0.50 (0.36 to 0.69) | 0.47 (0.34 to 0.65) |
| Log10 HIV viral load | |||||
| Continuous | 301 | – | – | 1.77 (1.47 to 2.14) | 1.80 (1.48 to 2.20) |
| sCD14 | |||||
| <Median | 151 | 73/230.6 | 31.7 | 1.0 | 1.0 |
| Median+ | 150 | 83/197.8 | 42.0 | 1.38 (1.01 to 1.90) | 1.18 (0.85 to 1.63) |
| CRP | |||||
| <Median | 151 | 78/218.7 | 35.7 | 1.0 | 1.0 |
| Median+ | 150 | 78/209.7 | 37.2 | 1.05 (0.77 to 1.43) | 0.95 (0.69 to 1.31) |
Significant HR are shown in bold.
*
Estimates for the adjusted HR include all variables listed in the table.
ART, antiretroviral therapy; CRT, C-reactive protein.